vs
Five9, Inc.（FIVN）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Five9, Inc.的季度营收约是Orthofix Medical Inc.的1.4倍（$300.3M vs $219.9M），Five9, Inc.同比增速更快（7.8% vs 2.0%），Five9, Inc.自由现金流更多（$77.3M vs $16.8M），过去两年Five9, Inc.的营收复合增速更高（10.3% vs 8.0%）
Five9是全球领先的云原生联络中心软件及解决方案供应商，服务零售、医疗、金融服务、科技等行业的各规模企业，提供全渠道客户互动、AI驱动自动化、劳动力管理、数据分析等工具，助力企业提升客户体验与运营效率。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FIVN vs OFIX — 直观对比
营收规模更大
FIVN
是对方的1.4倍
$219.9M
营收增速更快
FIVN
高出5.8%
2.0%
自由现金流更多
FIVN
多$60.5M
$16.8M
两年增速更快
FIVN
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $300.3M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 55.4% | 71.1% |
| 营业利润率 | 6.6% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 7.8% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.22 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FIVNOFIX
| Q4 25 | $300.3M | $219.9M | ||
| Q3 25 | $285.8M | $205.6M | ||
| Q2 25 | $283.3M | $203.1M | ||
| Q1 25 | $279.7M | $193.6M | ||
| Q4 24 | $278.7M | $215.7M | ||
| Q3 24 | $264.2M | $196.6M | ||
| Q2 24 | $252.1M | $198.6M | ||
| Q1 24 | $247.0M | $188.6M |
净利润FIVNOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $18.0M | $-22.8M | ||
| Q2 25 | $1.2M | $-14.1M | ||
| Q1 25 | $576.0K | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-4.5M | $-27.4M | ||
| Q2 24 | $-12.8M | $-33.4M | ||
| Q1 24 | $-7.1M | $-36.0M |
毛利率FIVNOFIX
| Q4 25 | 55.4% | 71.1% | ||
| Q3 25 | 55.0% | 72.2% | ||
| Q2 25 | 54.9% | 68.7% | ||
| Q1 25 | 55.0% | 62.8% | ||
| Q4 24 | 56.0% | 69.0% | ||
| Q3 24 | 53.8% | 68.7% | ||
| Q2 24 | 53.0% | 67.8% | ||
| Q1 24 | 53.6% | 67.5% |
营业利润率FIVNOFIX
| Q4 25 | 6.6% | 0.2% | ||
| Q3 25 | 5.6% | -8.3% | ||
| Q2 25 | -0.6% | -7.9% | ||
| Q1 25 | -1.9% | -25.2% | ||
| Q4 24 | 1.5% | -5.3% | ||
| Q3 24 | -5.8% | -9.6% | ||
| Q2 24 | -7.7% | -12.5% | ||
| Q1 24 | -8.4% | -15.6% |
净利率FIVNOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 6.3% | -11.1% | ||
| Q2 25 | 0.4% | -6.9% | ||
| Q1 25 | 0.2% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -1.7% | -13.9% | ||
| Q2 24 | -5.1% | -16.8% | ||
| Q1 24 | -2.9% | -19.1% |
每股收益（稀释后）FIVNOFIX
| Q4 25 | $0.22 | $-0.05 | ||
| Q3 25 | $0.21 | $-0.57 | ||
| Q2 25 | $0.01 | $-0.36 | ||
| Q1 25 | $0.01 | $-1.35 | ||
| Q4 24 | $0.16 | $-0.76 | ||
| Q3 24 | $-0.06 | $-0.71 | ||
| Q2 24 | $-0.17 | $-0.88 | ||
| Q1 24 | $-0.10 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $232.1M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $785.8M | $450.0M |
| 总资产 | $1.8B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FIVNOFIX
| Q4 25 | $232.1M | $82.0M | ||
| Q3 25 | $193.4M | $62.9M | ||
| Q2 25 | $205.5M | $65.6M | ||
| Q1 25 | $370.3M | $58.0M | ||
| Q4 24 | $362.5M | $83.2M | ||
| Q3 24 | $291.0M | $30.1M | ||
| Q2 24 | $175.7M | $26.4M | ||
| Q1 24 | $240.2M | $27.0M |
总债务FIVNOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益FIVNOFIX
| Q4 25 | $785.8M | $450.0M | ||
| Q3 25 | $775.3M | $442.5M | ||
| Q2 25 | $717.4M | $458.3M | ||
| Q1 25 | $664.3M | $458.3M | ||
| Q4 24 | $622.2M | $503.1M | ||
| Q3 24 | $565.6M | $525.9M | ||
| Q2 24 | $525.9M | $546.0M | ||
| Q1 24 | $483.6M | $570.3M |
总资产FIVNOFIX
| Q4 25 | $1.8B | $850.6M | ||
| Q3 25 | $1.8B | $832.6M | ||
| Q2 25 | $1.7B | $837.2M | ||
| Q1 25 | $2.1B | $823.1M | ||
| Q4 24 | $2.1B | $893.3M | ||
| Q3 24 | $2.0B | $867.9M | ||
| Q2 24 | $1.9B | $882.0M | ||
| Q1 24 | $1.9B | $906.0M |
负债/权益比FIVNOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $83.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $77.3M | $16.8M |
| 自由现金流率自由现金流/营收 | 25.8% | 7.6% |
| 资本支出强度资本支出/营收 | 2.1% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $201.2M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FIVNOFIX
| Q4 25 | $83.6M | $27.7M | ||
| Q3 25 | $59.2M | $12.4M | ||
| Q2 25 | $35.1M | $11.6M | ||
| Q1 25 | $48.4M | $-18.4M | ||
| Q4 24 | $49.8M | $23.7M | ||
| Q3 24 | $41.1M | $11.7M | ||
| Q2 24 | $19.9M | $9.0M | ||
| Q1 24 | $32.4M | $-18.6M |
自由现金流FIVNOFIX
| Q4 25 | $77.3M | $16.8M | ||
| Q3 25 | $48.7M | $2.5M | ||
| Q2 25 | $31.6M | $4.5M | ||
| Q1 25 | $43.7M | $-25.1M | ||
| Q4 24 | $40.5M | $15.2M | ||
| Q3 24 | $26.7M | $6.3M | ||
| Q2 24 | $13.1M | $-360.0K | ||
| Q1 24 | $20.4M | $-29.1M |
自由现金流率FIVNOFIX
| Q4 25 | 25.8% | 7.6% | ||
| Q3 25 | 17.0% | 1.2% | ||
| Q2 25 | 11.1% | 2.2% | ||
| Q1 25 | 15.6% | -13.0% | ||
| Q4 24 | 14.5% | 7.0% | ||
| Q3 24 | 10.1% | 3.2% | ||
| Q2 24 | 5.2% | -0.2% | ||
| Q1 24 | 8.3% | -15.4% |
资本支出强度FIVNOFIX
| Q4 25 | 2.1% | 4.9% | ||
| Q3 25 | 3.7% | 4.8% | ||
| Q2 25 | 1.2% | 3.5% | ||
| Q1 25 | 1.7% | 3.5% | ||
| Q4 24 | 3.3% | 4.0% | ||
| Q3 24 | 5.4% | 2.7% | ||
| Q2 24 | 2.7% | 4.7% | ||
| Q1 24 | 4.8% | 5.6% |
现金转化率FIVNOFIX
| Q4 25 | — | — | ||
| Q3 25 | 3.29× | — | ||
| Q2 25 | 30.38× | — | ||
| Q1 25 | 84.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FIVN
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
